レッドバイオテクノロジー市場- 世界の産業規模、シェア、動向、競合、機会、予測、2018-2028年

世界のレッドバイオテクノロジー市場は、2024～2028年の予測期間において目覚ましいCAGRで成長すると予想されています。

この背景には、遺伝子工学の需要拡大、生命を脅かす疾患の治療用新薬の開発、精密医療の生産拡大などの要因があります。

遺伝子工学の需要拡大

生物学的製剤の増加により、遺伝子工学の需要が増加しています。IQVIA Instituteのデータによると、生物学的製剤は米国全体の処方箋の2％であったが、純薬品支出の37％を占めていました。治療用抗体のような遺伝子組み換え生物の作製において、組み換えDNA技術のような遺伝子工学の利用が拡大していることが、世界中のレッドバイオテクノロジー市場の成長を後押ししています。CRISPRベースの遺伝子編集のような遺伝子編集などの技術もまた、市場に浸透しつつあり、それによって遺伝子工学におけるレッドバイオテクノロジーの応用を拡大することで市場の成長を支えています。さらに、レッドバイオテクノロジーは、組織工学技術を通じて、脊椎ディスク、人工骨、皮膚、軟骨の製造にも応用できることが分かっています。

生命を脅かす病気の治療のための新薬開発

レッドバイオテクノロジーは、遺伝子治療、臨床試験、診断、調査などの分野で応用されています。また、医薬品開発のための臨床試験の増加、バイオシミラーの受容と需要の増加が、最近のシナリオにおけるレッドバイオテクノロジーの成長に影響を与えています。レッドバイオテクノロジー市場のバイオ医薬品分野の拡大は、医薬品製造における臨床試験の増加とともに成長すると予想されます。例えば、2022年7月、ゲノム医療を生産する新興企業である調査（Replay）は、シード資金調達ラウンドで5,500万米ドルを投資し、新たな疾患ターゲットを発見し、疾患診断と治療を強化・改善するための様々な遺伝子型ゲノム研究を開発するための相互連携ステージを通じて、ゲノム医療を開発・変革しました。

精密医療の増加

世界中で慢性疾患が蔓延していることから、精密医療に対する需要が高まっています。世界保健機関（WHO）によると、がんは世界第2位の死因であり、世界で約960万人が死亡しています。世界のがん患者の増加に伴い、レッドバイオテクノロジー市場の成長も拡大しています。レッドバイオテクノロジーは、遺伝子検査やシークエンシング技術などを用いてこれらの疾患の原因を診断するために利用されるため、がんなどの疾患の診断、医薬品開発、治療において多くの有利な機会を見出しており、予測期間中の市場成長を後押しすると期待されています。これとともに、レッドバイオ技術は、ポリオワクチンと合併したB型肝炎や、A型肝炎と合併したDPTのような混合ワクチンの製造にも利用されており、これらすべてが予測期間の市場成長を支える重要な要素となっています。

利用可能なカスタマイズ

TechSciリサーチは、与えられた市場データを用いて、企業の特定のニーズに応じてカスタマイズを提供します。レポートでは以下のカスタマイズが可能です：

企業情報

• 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

• 市場の定義
• 市場の範囲
  • 対象市場
  • 調査対象年
  • 主要市場セグメンテーション

第2章 調査手法

• 調査目的
• ベースライン調査手法
• 主要産業パートナー
• 主要協会と二次情報源
• 予測手法
• データの三角測量と検証
• 仮定と限界

第3章 エグゼクティブサマリー

• 市場概要
• 主要市場セグメンテーションの概要
• 主要市場プレーヤーの概要
• 主要地域/国の概要
• 市場促進要因・課題・動向の概要

第4章 顧客の声

第5章 レッドバイオテクノロジー市場の展望。

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別
  • 用途別
  • エンドユーザー別
  • 企業別
  • 地域別
• 製品市場マップ

第6章 アジア太平洋地域のレッドバイオテクノロジー市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ
  • エンドユーザー
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第7章 欧州のレッドバイオテクノロジー市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 北米のレッドバイオテクノロジー市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のレッドバイオテクノロジー市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのレッドバイオテクノロジー市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品開発

第13章 競合情勢

• Business Overview
• Company Snapshot
• Products & Services
• Financials（In case of listed companies）
• Recent Developments
• SWOT Analysis
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences
  • Regeneron Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Bruker
  • Merck KGaA
  • Celgene Corporation
  • Amgen, Inc.
  • Biogen, Inc.,

第14章 戦略的提言

Global Red Biotechnology Market is expected to grow with an impressive CAGR in the forecast period of 2024-2028. This can be attributed to factors such as the growing demand for genetic engineering, the development of new medicines for the treatment of life-threatening diseases, and the increased production of precision medicine.

Red Biotechnology focuses on the therapeutic or diagnostic use of living cells and their components to develop novel medical treatments and cures for diseases and health issues. It includes the creation of a wide range of goods, including medicines, diagnostic instruments, vaccines, gene treatments, and other products for the treatment and prevention of different diseases.

The growing demand for precision medicine is enhancing the market opportunities and increasing demand for the global red biotechnology market.

Growing Demand for Genetic Engineering

An increase in demand for genetic engineering has been observed due to an increase in biologic drugs. According to IQVIA Institute data, biologic drugs represented 2 percent of all United States prescriptions but comprised 37% net drug spending. The growing use of genetic engineering, such as recombinant DNA technology, in creating genetically modified organisms, such as therapeutic antibodies, is propelling the growth of the red biotechnology market across the globe. The technologies, such as gene editing, such as CRISPR-based genetic editing, are also becoming much prevalent in the market and thereby are supporting the market growth by expanding the applications of red biotechnology in genetic engineering. Additionally, red biotechnology is found to have applications in the production of spinal discs, artificial bones, skin, and cartilage through tissue engineering techniques.

Development of new medicines for the treatment of life-threatening diseases

Red biotechnology has found applications in fields such as gene therapy, clinical trials, diagnostics, and research. Also, the growing number of clinical trials for the development of drugs, along with the rise in acceptance and demand for biosimilars, affect the growth of red biotechnology in the recent scenario. The expansion of the biopharmaceutical sector of the red biotechnology market is expected to grow with increasing clinical trials in medicine production. For instance, In July 2022, Replay-a genomic medicine-producing startup, invested USD55 million in a seed funding round to develop and transform genomic medicine through an interlinking stage for developing various genotype genomic research to discover new disease targets and enhance and improve the disease diagnosis & treatment.

Increased production of precision medicine

The growing prevalence of chronic diseases across the world is creating a rising demand for precision medicine. According to the World Health Organization (WHO), cancer is the second leading cause of death globally and has recorded around 9.6 million deaths globally. With the increasing number of cancer patients worldwide, the growth of the red biotechnology market is also expanding as it is utilized for diagnosing the reason for these diseases by using genetic testing and sequencing techniques, etc., and thereby has found many lucrative opportunities in diagnosis, drug development and treatment for diseases such as cancer and is thereby expected to bolster market growth in the forecast period. Along with this, red biotechnology is utilized in combined vaccine production, such as Hepatitis B, merged with the polio vaccine, and DPT merged with Hepatitis A, and this all together is of great importance to support the market growth in the forecast period.

Recent Developments

In June 2022, Bluebird Bio developed a new gene therapy that is being evaluated by the United States Food Drug and Administration regarding the treatment of (CALD) cerebral adrenoleukodystrophy (a genetic condition that damages the membrane myelin sheath of the brain) in patients under adolescent age.

Market Segmentation

Global Red Biotechnology Market is segmented based on the product type, application, end-user, region, and competitive landscape. Based on product type, the market is segmented into diagnostic reagents, human vaccines, blood products, gene recombinant drugs, and others. Based on application, the market is segmented into biopharmaceutical production, gene therapy, genetic testing, pharmacogenomics, drug discovery, and others. Based on end-user, the market is segmented into pharmaceutical and biotechnology companies, CMO & CRO, research institutes, and others.

Market Players

Pfizer, Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche, Ltd., Bruker, Merck KGaA, Celgene Corporation, Amgen, Inc., etc., are some of the major players operating in the Global Red Biotechnology Market.

Report Scope

In this report, Global Red Biotechnology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Red Biotechnology Market, By Product Type:

• Diagnostic Reagents
• Human Vaccines
• Blood Products
• Gene Recombinant drugs
• Others

Red Biotechnology Market, By Application:

• Biopharmaceutical Production
• Gene Therapy
• Genetic Testing
• Pharmacogenomics
• Drug Discovery
• Others

Red Biotechnology Market, By End-User:

• Pharmaceutical and Biotechnology companies
• CMO & CRO
• Research Institute
• Others

Red Biotechnology Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

• South America
  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Red Biotechnology Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered.
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Red Biotechnology Market Outlook.

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Diagnostic Reagents, Human Vaccines, Blood Products, Gene Recombinant Drugs and Others)
  • 5.2.2. By Application (Biopharmaceutical Production, Gene Therapy, Genetic Testing, Pharmacogenomics, Drug Discovery, and Others)
  • 5.2.3. By End-User (Pharmaceutical and Biotechnology companies, CMO & CRO, Research Institute and Others)
  • 5.2.4. By Company (2022)
  • 5.2.5. By Region
• 5.3. Product Market Map

6. Asia-Pacific Red Biotechnology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. Product Type
  • 6.2.2. End-User
  • 6.2.3. By Country
• 6.3. Asia-Pacific: Country Analysis
  • 6.3.1. China Red Biotechnology Market Outlook.
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. Product Type
      • 6.3.1.2.2. End-User
  • 6.3.2. India Red Biotechnology Market Outlook.
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. Product Type
      • 6.3.2.2.2. End-User
  • 6.3.3. South Korea Red Biotechnology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. Product Type
      • 6.3.3.2.2. End-User
  • 6.3.4. Japan Red Biotechnology Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. Product Type
      • 6.3.4.2.2. End-User
  • 6.3.5. Australia Red Biotechnology Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. Product Type
      • 6.3.5.2.2. End-User

7. Europe Red Biotechnology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. Product Type
  • 7.2.2. End-User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Red Biotechnology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. Product Type
      • 7.3.1.2.2. End-User
  • 7.3.2. Germany Red Biotechnology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. Product Type
      • 7.3.2.2.2. End-User
  • 7.3.3. United Kingdom Red Biotechnology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. Product Type
      • 7.3.3.2.2. End-User
  • 7.3.4. Italy Red Biotechnology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. Product Type
      • 7.3.4.2.2. End-User
  • 7.3.5. Spain Red Biotechnology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. Product Type
      • 7.3.5.2.2. End-User

8. North America Red Biotechnology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. Product Type
  • 8.2.2. End-User
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Red Biotechnology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. Product Type
      • 8.3.1.2.2. End-User
  • 8.3.2. Mexico Red Biotechnology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. Product Type
      • 8.3.2.2.2. End-User
  • 8.3.3. Canada Red Biotechnology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. Product Type
      • 8.3.3.2.2. End-User

9. South America Red Biotechnology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. Product Type
  • 9.2.2. End-User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Red Biotechnology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. Product Type
      • 9.3.1.2.2. End-User
  • 9.3.2. Argentina Red Biotechnology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. Product Type
      • 9.3.2.2.2. End-User
  • 9.3.3. Colombia Red Biotechnology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. Product Type
      • 9.3.3.2.2. End-User

10. Middle East and Africa Red Biotechnology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. Product Type
  • 10.2.2. End-User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Red Biotechnology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. Product Type
      • 10.3.1.2.2. End-User
  • 10.3.2. Saudi Arabia Red Biotechnology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. Product Type
      • 10.3.2.2.2. End-User
  • 10.3.3. UAE Red Biotechnology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. Product Type
      • 10.3.3.2.2. End-User
  • 10.3.4. Kuwait Red Biotechnology Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. Product Type
      • 10.3.4.2.2. End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Mergers & Acquisitions
• 12.3. Product Developments

13. Competitive Landscape

• 13.1. Business Overview
• 13.2. Company Snapshot
• 13.3. Products & Services
• 13.4. Financials (In case of listed companies)
• 13.5. Recent Developments
• 13.6. SWOT Analysis
  • 13.6.1. Pfizer, Inc.
  • 13.6.2. Takeda Pharmaceutical Company Limited
  • 13.6.3. Gilead Sciences
  • 13.6.4. Regeneron Pharmaceuticals, Inc.
  • 13.6.5. F. Hoffmann-La Roche, Ltd.
  • 13.6.6. Bruker
  • 13.6.7. Merck KGaA
  • 13.6.8. Celgene Corporation
  • 13.6.9. Amgen, Inc.
  • 13.6.10. Biogen, Inc.,

14. Strategic Recommendations